Does EPA compete with arachidonic acid for COX and LOX enzymes to reduce inflammatory eicosanoids?

Eicosapentaenoic acid (EPA) acts as a critical modulator of the inflammatory response by physically competing with arachidonic acid (AA) for access to key enzymes. This biochemical competition is a primary mechanism through which omega-3 fatty acids exert their anti-inflammatory effects.

Mechanistic basis of enzyme competition

EPA functions as a competitive inhibitor of arachidonic acid for the active sites of cyclooxygenase (COX) and lipoxygenase (LOX) enzymes. Because both EPA and AA are 20-carbon polyunsaturated fatty acids, they share high structural similarity, allowing them to bind to the same enzymatic pockets.

• Kinetics: Studies show that EPA increases the apparent Michaelis constant (Km) for AA, confirming competitive inhibition at the substrate-binding site.
• Substrate Preference: While AA often has a higher binding affinity for COX-1, COX-2, and 5-LOX, high concentrations of EPA (achieved through supplementation) can effectively outcompete AA, reducing the conversion of AA into pro-inflammatory mediators.

Signaling shifts and lipidome remodeling

Increasing the EPA:AA ratio leads to a profound shift in the lipidomic profile. EPA displaces AA from cell membrane phospholipids, which reduces the pool of AA available for inflammatory signaling.

• Alternative Eicosanoids: As EPA replaces AA as the primary substrate, enzymatic output shifts from potent 2-series prostaglandins (e.g., PGE2) and 4-series leukotrienes (e.g., LTB4) toward 3-series prostaglandins and 5-series leukotrienes, which generally possess significantly lower inflammatory potency.
• Pro-resolving Mediators: EPA serves as the direct precursor for specialized pro-resolving mediators (SPMs), specifically E-series resolvins (RvE1, RvE2). These molecules actively promote the resolution phase of inflammation, facilitating the return to tissue homeostasis.

Bottom line

EPA reduces inflammation by competing with arachidonic acid for COX and LOX enzymes, effectively shifting the metabolic output from pro-inflammatory mediators to less-inflammatory 3-series eicosanoids and pro-resolving resolvins. This mechanism is highly supported by evidence of lipidomic remodeling and enzyme kinetics.